⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 9, 2017Journal of Nuclear MedicineOpen Access

Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors

Clément Morgat Gaëtan MacGrogan Véronique Brouste Valérie Velasco Nicolas Sévenet Hervé Bonnefoi Philippe Fernandez Marc Debled Elif Hindié

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Because GRPR is overexpressed in a high percentage of ER-positive tumors, GRPR targeting offers wide perspectives for imaging and treatment in patients with ER-positive breast cancer, using recently developed radiolabeled GRPR ligands.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Morgat et al. (2017) studied this question.

synapsesocial.com/papers/6a033e4a200d7a04bd755d99 https://doi.org/10.2967/jnumed.116.188011

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Impact of PSMA PET/CT Staging on Long-Term Outcomes in Patients with Clinically Localized Prostate Cancer: Results of a Large Single-Center CohortJournal of Nuclear Medicine · 2026
2Botulinum Toxin Plus Transdermal Scopolamine Reduces Salivary Gland Uptake in Patients Undergoing Tandem Radiopharmaceutical Therapy with [ 225 Ac]Ac- and [ 177 Lu]Lu-PSMA RadioligandsJournal of Nuclear Medicine · 2026
3Predicting [ 90 Y]Y-FAPI-46 Tumor Absorbed Dose from Single-Time-Point [ 68 Ga]Ga-FAPI-46 PET/CT ImagingJournal of Nuclear Medicine · 2026
4Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic StudyJournal of Nuclear Medicine · 2026
5Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical TherapyJournal of Nuclear Medicine · 2026

Should Molecular Subtype Influence the Interpretation of Serial 68 Ga-HER2 PET/CT During Neoadjuvant Therapy?Journal of Nuclear Medicine · 2026
Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center StudyJournal of Nuclear Medicine · 2026
Symptomatic Hyperkinetic Gallbladder: An Unrecognized Indication for CholecystectomyJournal of Nuclear Medicine · 2026
18 F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 ImmunohistochemistryJournal of Nuclear Medicine · 2026
TBR max After FDA Approval of [ 18 F]FET PET: 1 Name, 2 MeasurementsJournal of Nuclear Medicine · 2026

More from Journal of Nuclear Medicine

More from Centre National de la Recherche Scientifique

More from Inserm

More from Université de Bordeaux

More from Institut Bergonié

More from Bordeaux Population Health

More from Institut de Neurosciences Cognitives et Intégratives d’Aquitaine